OL Oncology Letters 1792-1074 1792-1082 D.A. Spandidos 10.3892/ol.2014.2239 ol-08-03-0993 Articles Matrigel induces L-plastin expression and promotes L-plastin-dependent invasion in human cholangiocarcinoma cells CHAIJANSUTHIDARAK1 ROYTRAKULSITTIRUK2 MUTIRANGURAAPIWAT3 LEELAWATKAWIN4 Inter-Departmental Program in Biomedical Sciences, Faculty of the Graduate School, Chulalongkorn University, Bangkok 10330, Thailand The National Center for Genetic Engineering and Biotechnology, National Science and Technology Development Agency, Pathumtani 12120, Thailand Center for Excellence in the Molecular Genetics of Cancer and Human Diseases, Department of Anatomy, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand Department of Surgery, Rajavithi Hospital, Bangkok 10400, Thailand Correspondence to: Dr Kawin Leelawat, Department of Surgery, Rajavithi Hospital, 2 Prayathai Road, Bangkok 10400, Thailand, E-mail: kawin.leelawat@gmail.com 9 2014 11 06 2014 8 3 993 1000 07 06 2013 20 12 2013 Copyright © 2014, Spandidos Publications 2014 This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.

The function of the extracellular matrix (ECM) in the tumor microenvironment is not limited to forming a barrier against tumor invasion. As demonstrated in pathological specimens, cholangiocarcinoma samples exhibit an enrichment of the ECM surrounding the tumor cells. In this study, we examined involvement of the ECM in the regulation of the invasiveness of cholangiocarcinoma cells. The RMCCA1 cholangiocarcinoma cell line was cultured in culture plates either with or without a coating of reconstituted ECM basement membrane preparation (BD Matrigel matrix). In vitro invasion assays were then performed. In addition, the protein expression profile of the cell line was examined using two-dimensional gel electrophoresis and liquid chromatography-tandem mass spectrometry. The proteins expressed and their functional associations with cancer progression were determined. Culturing the RMCCA1 cell line in the BD Matrigel matrix induced cell invasion. Numerous proteins were induced by culturing the RMCCA1 cells in the matrix gel. The expression of L-plastin, an actin-binding protein, was significantly upregulated. The knockdown of L-plastin expression by siRNA silencing significantly suppressed the cellular response to matrix gel-stimulated cancer cell invasion. The ECM promotes the invasiveness of cholangiocarcinoma cells by upregulating L-plastin. These findings suggest the potential exploitation of this mechanism as a means of inhibiting the invasiveness of cholangiocarcinoma cells.

 cholangiocarcinoma extracellular matrix cancer cell invasion L-plastin liquid chromatography-tandem mass spectrometry Introduction

Cholangiocarcinoma, an aggressive malignant tumor that develops from the bile duct epithelium, is associated with local invasiveness and a high rate of metastasis (1,2). The worldwide incidence and mortality rates associated with cholangiocarcinoma have risen over the past three decades. In Thailand, the annual incidence of cholangiocarcinoma is 87 per 100,000 inhabitants (3). In the United States, the most commonly recognized risk factor for cholangiocarcinoma is primary sclerosing cholangitis (4). However, in Southeast Asia and particularly in Thailand, infection with hepatobiliary flukes (Opisthorchis viverrini) is the most common risk factor for cholangiocarcinoma (5). Therapeutic options for cholangiocarcinoma patients are limited, as this type of cancer responds poorly to chemotherapy and radiation therapy. Surgery is thus the only potentially effective treatment for cholangiocarcinoma. However, typical five-year survival rates of 32–50% are achieved only by a small number of patients with negative histological margins at the time of surgery (6–8). Therefore, the understanding of the mechanisms involved in cancer cell invasion and metastasis may be useful in developing new therapeutic options for cholangiocarcinoma patients.

The function of the extracellular matrix (ECM) in the tumor microenvironment is not limited to forming a barrier against tumor invasion. Previous studies have indicated that interactions between cancer cells and the ECM play an important role in cancer progression. The molecular components of the ECM, such as fibronectin, laminin, collagen and heparin sulfate proteoglycans, communicate with cancer cells and modulate a variety of cellular functions required for cancer cells to exhibit invasive and metastatic properties (9–11). Numerous results from pathological studies have indicated that cholangiocarcinoma cells are surrounded by a dense sheath of connective tissue that contains the ECM (12–14). However, there have been no studies to date regarding the definitive role that the ECM plays in cholangiocarcinoma cell invasion. Therefore, we aimed to investigate the involvement of the ECM in cholangiocarcinoma cell invasion.

 Materials and methods Cell cultures

The RMCCA1 human cholangiocarcinoma cell line, originally derived from a cholangiocarcinoma patient (15), was grown in Ham’s F12 medium (Gibco, Grand Island, NY, USA) supplemented with 10% fetal bovine serum (Gibco) at 37°C in a 5% CO2 humidified atmosphere.

 Cell invasion assay

To study the mechanism of cancer cell invasion in vitro, RMCCA1 cells were cultured in BD Matrigel matrix (BD Biosciences, Bedford, MA, USA) for 0–24 h. Next, cancer cells were seeded into porous cell culture insert cups (BD Biosciences) each containing a layer of matrix gel. The number of cancer cells that invaded through the basement membrane within 24 h was assessed by staining the cells with crystal violet (Sigma-Aldric, St. Louis, MO, USA) (16).

 Two-dimensional (2D) gel electrophoresis

2D gel electrophoresis was performed for the analysis of proteins extracted from cholangiocarcinoma cells cultured in uncoated and 24-h matrix gel-coated plates. Each electrophoresis gel contained three pooled samples from the cell culture plates. Six gels were prepared in biological triplicates from the uncoated and matrix gel-coated plates. Protein samples (500 μg) were applied to 18-cm immobilized pH gradient (IPG) gel strips (pH 3–10; GE Healthcare, Uppsala, Sweden) by cup loading near the anodic ends of the strips. Isoelectric focusing (IEF) was performed using an Ettan IPGphor Manifold on an Ettan IPGphor isoelectric focusing unit (GE Healthcare) for 32,000 Vh at 20°C. Following IEF, each gel strip was equilibrated with equilibration buffer. The IPG strips were then loaded and run on 12.5% acrylamide gels (GE Healthcare) using the Ettan DALTsix electrophoresis system (GE Healthcare). The run was stopped after the bromophenol blue dye front had run off the bottom of the gels. The gels were then stained with colloidal Coomassie Blue (GE Healthcare).

 2D image analysis

The proteins were visualized using an ImageScanner (GE Healthcare). The gel images were analyzed to determine differential protein expression profiles using ImageMaster 2D Platinum software (GE Healthcare). Student’s t-test was used for statistical analysis and P<0.05 was considered to indicate a statistically significant difference.

 Protein identification by liquid chromatography-tandem mass spectrometry (LC-MS/MS) In-gel digestion

LC-MS/MS was performed by the Proteomics Laboratory, Genome Institute, National Science and Technology Development Agency (Pathumthani, Thailand). Following 2D analysis, an in-gel digestion was performed. Briefly, after the protein spots were excised, the gel plugs were dehydrated with 100% acetonitrile (ACN), reduced with 10 mM DTT in 10 mM ammonium bicarbonate at room temperature for 1 h and alkylated at room temperature for 1 h in the dark in the presence of 100 mM iodoacetamide in 10 mM ammonium bicarbonate. Following alkylation, the gel pieces were dehydrated twice with 100% ACN for 5 min. For the in-gel digestion of the proteins, 10 μl trypsin solution (20 ng/μl trypsin in 50% ACN/10 mM ammonium bicarbonate) was added to the gels followed by incubation at room temperature for 20 min. Next, 20 μl 30% ACN was added to keep the gels immersed throughout digestion. The gels were incubated at 37°C overnight. To extract the peptide digestion products, 30 μl 50% ACN in 0.1% formic acid was added to the gels, which were then incubated at room temperature for 10 min in a shaker. The extracted peptides were collected and pooled in a new tube. The pooled extracted peptides were dried by vacuum centrifugation at 2,500 × g for 10 min and stored at −80°C until further mass spectrometric analysis.

 LC-MS/MS analysis

The LC-MS/MS analysis of the digested peptide mixtures was performed using a Waters SYNAPT™ HDMS™ system (Waters, Milford, MA, USA). The 1D-nanoLC was performed with a Waters nanoACQUITY UPLC system (Waters). Tryptic digests (4 μl) were injected onto an reversed-phase analytical column (20 cm × 75 μm) packed with 1.7-μm ethylene bridged hybrid C18 material (Waters). The peptides were eluted with a linear gradient of 2–40% acetonitrile developed over 30 min at a flow rate of 1000 nl/min. This elution was followed by a 10-min 80% acetonitrile treatment to clean the column before using 2% acetonitrile for the next sample. The effluent samples were electrosprayed into a mass spectrometer (SYNAPT HDMS system) for MS/MS analysis of the peptides, and spectral data were generated for further protein identification by matching against hits in a database search.

Mass lists in the form of Mascot generic files were created and used as the inputs for the Mascot MS/MS Ion web-based search functionality at the National Center for Biotechnology Information non-redundant database (www.matrixscience.com). The default search parameters were applied as follows: Enzyme, trypsin; taxonomy, Homo sapiens (human); maximum missed cleavages, 1; fixed modifications, carbamidomethyl (C); variable modifications, oxidation (M); peptide tolerance, ±1.2 Da; MS/MS tolerance, ±0.6 Da; peptide charge, 1+, 2+ and 3+; and instrument, ESI-QUAD-TOF.

 Western blot analysis

Protein extracts isolated from the cells cultured in the uncoated and 24-h matrix gel-coated plates were separated by 12% SDS-PAGE and then transferred onto a nitrocellulose membrane (GE Healthcare). The membrane was subsequently incubated with monoclonal antibodies against L-plastin (1:50; Santa Cruz Biotechnology, Santa Cruz, CA, USA) and β-actin (1:500; Cell Signaling Technology, Danvers, MA, USA). Horseradish peroxidase-conjugated anti-mouse immunoglobulin G (IgG) and anti-rabbit IgG at 1:5,000 dilutions were used as secondary antibodies (GE Healthcare). The blots were visualized using an ECL Plus detection kit and Hyperfilm ECL (GE Healthcare). The western blot results were quantified using densitometer and image analysis software (ImageScanner III and ImageQuant TL; GE Healthcare, Uppsala, Sweden).

 Inhibition of L-plastin expression using transient siRNA transfection

L-plastin siRNA (Santa Cruz Biotechnology) was used to knock down L-plastin gene expression. A fluorescein-labeled, double-stranded RNA duplex (BLOCK-iT™ Fluorescent Oligo; Invitrogen, Melville, NY, USA) was designed as a control. The siRNA molecules were diluted in Opti-MEM® I Medium without serum (Gibco) and mixed gently. Next, Lipofectamine™ 2000 (Invitrogen) was diluted in Opti-MEM I Medium without serum, mixed gently and incubated for 5 min at room temperature. The diluted siRNA molecules and diluted Lipofectamine 2000 were then combined. The mixtures were incubated for 20 min at room temperature to allow for complex formation to occur. The siRNA molecule-Lipofectamine 2000 complexes were added to each well containing cells and medium, and mixed gently by rocking the plate back and forth. The cells were incubated at 37°C in a CO2 incubator for 6 h. Next, the growth medium was replaced after 6 h, and the cells were harvested 24 h after transfection. Western blotting analysis using the L-plastin antibody was performed to assess the degree of L-plastin gene expression knockdown.

 Immunofluorescence microscopy

Cells (5×104) were incubated with the primary antibody, anti-L-Plastin (1:10), for 1 h at room temperature. The cells were then washed and incubated with the appropriate secondary antibody (Alexa Fluor 594, anti-mouse; Molecular Probes, Grand Island, NY, USA) for 1 h at room temperature. The actin filaments (F-actin) in the cell cytoplasm were stained with Alexa Fluor 488 phalloidin (Molecular Probes), and the nuclei were stained with TOPO3 (Molecular Probes). The cover slides were removed from the plates and mounted with antifade on the slides. Cell images were captured with a confocal scanning biological microscope (FV1000; Olympus, Tokyo, Japan).

 Immunohistochemical staining

The study was performed with approval from the Ethics Committee of Rajavithi Hospital (Bangkok, Thailand). Paraffinized sections on glass slides were subjected to L-plastin detection by standard immunohistochemical technique. Sections were hybridized overnight at 4°C with a 1:50 dilution of L-plastin antibody (Abcam, Cambridge, MA, USA), followed by incubation with the secondary antibody, polyclonal Goat Anti-Mouse IgG (Abcam), conjugated to horseradish peroxidase that catalyzes a color-producing reaction (Abcam). The signals were visualized under high power magnification (x200) on an Olympus BH2 microscope.

 Statistical analysis

Continuous values for the observed levels in the invasion assay were expressed as the mean and standard deviation. One-way analysis of variance was used for the analysis of the multiple variables of the cell invasion assay. Student’s t-test was employed to evaluate the mean differences in the intensity volume of each corresponding spot between the two groups of samples. The statistical analysis of the immunohistochemical studies was performed using either the χ2 test or Fisher’s exact test. P<0.05 was considered to indicate a statistically significant difference.

 Results Culturing cholangiocarcinoma cells in matrix gel increases their invasiveness

RMCCA1 cholangiocarcinoma cells were incubated in matrix gel for 0–24 h, and invasion assays were then performed. The results showed that a significantly higher number of cholangiocarcinoma cells that were cultured in matrix gel invaded through the insertion cup compared with that observed with the cells that were cultured on uncoated plates (P<0.001; Fig. 1).

 Proteomic study of cholangiocarcinoma cells cultured in matrix gel

To investigate the proteins potentially involved in cholangiocarcinoma cell invasion, cholangiocarcinoma cells were cultured in plates coated with or without matrix gel. Next, 2D gel electrophoresis using pH 3–10 Linear IPG strips was performed to identify the protein expression profiles of these cells. Approximately 800 protein spots were detected by colloidal Coomassie staining. Quantitative intensity and statistical analyses identified 129 protein spots with significantly altered expression levels in matrix gel culture compared with the uncoated culture system. Of these 129 proteins, 60 proteins exhibited greater than two-fold upregulation as determined by mass spectrometry. All the identified proteins were in the expected ranges of their theoretical molecular masses and pI values (Table I). We report for the first time that the ECM plays a major role in the regulation of cholangiocarcinoma cell invasion. Based on 2D electrophoresis results, we identified the proteins that were upregulated when cholangiocarcinoma cells were cultured in matrix gel for 24 h.

 Functional studies of protein expression in cholangiocarcinoma cells cultured in matrix gel

The identified proteins that exhibited significant changes in expression levels were classified using a UniProtKB search for protein functional analysis in the species Homo sapiens (human). Based on the search results, these proteins are involved in energy metabolism, molecular chaperoning, cytoskeleton functions, actin binding, translation, transcription regulation, calcium ion binding, cell structure and signal transduction (Fig. 2A). Contact with the ECM and the remodeling of the actin cytoskeleton can drive cancer cell motility and promote invasion. L-plastin is one of the actin-binding proteins that exhibited a high level of protein expression in cholangiocarcinoma cells cultured in matrix gel. We performed a western blot analysis to confirm the results of the proteomic study. The results showed that a high level of L-plastin expression was identified in RMCCA1 cells cultured in matrix gel (Fig. 2B). A previous study demonstrated that L-plastin localizes to actin-rich membrane structures involved in locomotion, adhesion and immune defense, thereby implying that L-plastin is involved in the organization of the actin cytoskeleton (17). In addition, L-plastin has also been detected in solid tumors of epithelial and mesenchymal origin and has been suggested to be involved in cancer cell invasion (18). In line with these observations, we found that the number of cholangiocarcinoma cell invasion events significantly decreased when the expression of L-plastin was inhibited with L-plastin siRNA.

 Effect of L-plastin on cholangiocarcinoma cell invasion

To determine whether the expression of L-plastin is associated with cholangiocarcinoma cell invasion, we knocked down the expression of L-plastin using L-plastin siRNA. The western blot (Fig. 3A) and immunofluorescence studies (Fig. 3B) demonstrated that L-plastin was significantly downregulated after transfecting the RMCCA1 cells with L-plastin siRNA. Moreover, the invasion assay showed that the number of cancer cell invasion events was significantly decreased with the L-plastin siRNA cells compared with those treated with the control dsRNA (P<0.001; Fig. 3C).

 Detection of L-plastin expression in paraffin-embedded cholangiocarcinoma specimens

The expression of L-plastin was determined by immunohistochemistry in 24 paraffin-embedded cholangiocarcinoma specimens. In these cancerous tissues, L-plastin-specific signals were localized mainly in the nucleus and cytoplasm of cholangiocarcinoma cells that invaded the basement membrane and presented as mesenchymal-like cells (Fig. 4). However, cholangiocarcinoma cells that were arranged in a granular structure were negative for L-plastin.

We found that 37.5% (9/24) of the cholangiocarcinoma specimens were positive for the L-plastin expression signal. The correlation between the expression of L-plastin and the clinical characteristics is shown in Table II. The expression of L-plastin in cholangiocarcinoma was detected in all stages of the disease.

 Discussion

We report for the first time that the ECM plays a major role in the regulation of cholangiocarcinoma cell invasion. Based on 2D electrophoresis results, we identified the proteins that were upregulated when cholangiocarcinoma cells were cultured in matrix gel for 24 h. L-plastin, a major F-actin-bundling protein, was significantly upregulated in matrix-gel-coated plates compared with uncoated plates. The results were confirmed by western blotting, as L-plastin exhibited higher expression levels in RMCCA1 cells cultured in matrix-coated plates. A previous study demonstrated that L-plastin localizes to actin-rich membrane structures involved in locomotion, adhesion and immune defense, thereby implying that L-plastin is involved in the organization of the actin cytoskeleton (17). In addition, L-plastin has also been detected in solid tumors of epithelial and mesenchymal origin and has been suggested to play a role in cancer cell invasion (18). In line with these observations, we found that the number of cholangiocarcinoma cell invasion events significantly decreased when the expression of L-plastin was inhibited with L-plastin siRNA.

Confirming the results of prior studies, we observed that L-plastin is located in the nuclei and cytoplasm of cancer cells (17,19). The functional relevance of the nucleocytoplasmic shuttling of L-plastin currently remains unclear. L-plastin may be involved in the regulation of nuclear actin, which is an essential component of the pre-initiation complex and cooperates with polymerases I, II and III in the regulation of gene expression (20). The formation of protrusive structures is driven by spatially and temporally regulated actin polymerization at the leading edge of the cell (21). Further studies should be performed to elucidate the involvement of L-plastin localization in cholangiocarcinoma cells. We found that L-plastin was primarily expressed in mesenchymal-like cholangiocarcinoma cells. These findings suggest that L-plastin expression is associated with the epithelial-mesenchymal transition of cholangiocarcinoma cells.

To understand whether our in vitro findings are also relevant in vivo, we performed immunohistochemical analyses of tumor specimens derived from cholangiocarcinoma patients. Our analyses demonstrated that L-plastin is expressed in cholangiocarcinoma specimens. However, the level of expression was not significantly correlated with tumor differentiation, lymph node or metastatic status. This finding is in contrast to that reported for colorectal cancer, in which the expression of L-plastin is significantly correlated with cancer staging (22). Variations in the biological features of the tumors and the limited number of specimens in our study may account for these differences. In conclusion, attachment to the ECM promotes cholangiocarcinoma cell progression by inducing L-plastin expression. Understanding this mechanism may help to identify a novel molecular target for the development of an effective therapy for cholangiocarcinoma patients.

 Acknowledgements

The authors would like to thank Ms. Atchara Paemanee at The National Center for Genetic Engineering and Biotechnology for the mass spectrometry assistance. This study was supported by Rajavithi Hospital (Bangkok, Thailand) and the Thailand Graduate Institute of Science and Technology (TGIST), the National Science and Technology Development Agency (Pathum Thani, Thailand).

 References LeelawatKNarongSWannaprasertJLeelawatSSerum NGAL to clinically distinguish cholangiocarcinoma from benign biliary tract diseasesInt J Hepatol20118735482011 SrisomsapCSawangareetrakulPSubhasitanontPProteomic studies of cholangiocarcinoma and hepatocellular carcinoma cell secretomesJ Biomed Biotechnol20104371432010 SripaBPairojkulCCholangiocarcinoma: lessons from ThailandCurr Opin Gastroenterol243493562008 Van BeersBEDiagnosis of cholangiocarcinomaHPB (Oxford)1087932008 KaewpitoonNKaewpitoonSJPengsaaPOpisthorchiasis in Thailand: review and current statusWorld J Gastroenterol14229723022008 ChamberlainRSBlumgartLHHilar cholangiocarcinoma: a review and commentaryAnn Surg Oncol755662000 NakagohriTKinoshitaTKonishiMTakahashiSGotohdaNSurgical outcome and prognostic factors in intrahepatic cholangiocarcinomaWorld J Surg32267526802008 WashburnWKLewisWDJenkinsRLAggressive surgical resection for cholangiocarcinomaArch Surg1302702761995 FriedlPZänkerKSBröckerEBCell migration strategies in 3-D extracellular matrix: differences in morphology, cell matrix interactions, and integrin functionMicrosc Res Tech433693781998 LomberkGThe extracellular matrix and cell migrationPancreatology10452010 PainterKJArmstrongNJSherrattJAThe impact of adhesion on cellular invasion processes in cancer and developmentJ Theor Biol264105710672010 AlvaroDMancinoMGNew insights on the molecular and cell biology of human cholangiopathiesMol Aspects Med2950572008 PrakobwongSPinlaorSYongvanitPSithithawornPPairojkulCHirakuYTime profiles of the expression of metalloproteinases, tissue inhibitors of metalloproteases, cytokines and collagens in hamsters infected with Opisthorchis viverrini with special reference to peribiliary fibrosis and liver injuryInt J Parasitol398258352009 SripaBMairiangEThinkhamropBAdvanced periductal fibrosis from infection with the carcinogenic human liver fluke Opisthorchis viverrini correlates with elevated levels of interleukin-6Hepatology50127312812009 RattanasinganchanPLeelawatKTreepongkarunaSAEstablishment and characterization of a cholangiocarcinoma cell line (RMCCA-1) from a Thai patientWorld J Gastroenterol12650065062006 LeelawatKLeelawatSNarongSHongengSRoles of the MEK1/2 and AKT pathways in CXCL12/CXCR4 induced cholangiocarcinoma cell invasionWorld J Gastroenterol13156115682007 DelanoteVVandekerckhoveJGettemansJPlastins: versatile modulators of actin organization in (patho)physiological cellular processesActa Pharmacol Sin267697792005 SamstagYKlemkeMEctopic expression of L-plastin in human tumor cells: diagnostic and therapeutic implicationsAdv Enzyme Regul471181262007 DelanoteVVan ImpeKDe CorteVMolecular basis for dissimilar nuclear trafficking of the actin-bundling protein isoforms T- and L-plastinTraffic63353452005 Ben-AriYBrodyYKinorNThe life of an mRNA in space and timeJ Cell Sci123176117742010 YamaguchiHCondeelisJRegulation of the actin cytoskeleton in cancer cell migration and invasionBiochim Biophys Acta17736426522007 OtsukaMKatoMYoshikawaTDifferential expression of the L-plastin gene in human colorectal cancer progression and metastasisBiochem Biophys Res Commun2898768812001

RMCCA1 cholangiocarcinoma cell invasion assays. (A) Box plots comparing the number of cholangiocarcinoma cell invasion events in cells cultured in matrix gel and controls (*P<0.001 by analysis of variance, compared with the control). (B) Micrographs of cholangiocarcinoma cell invasion (cholangiocarcinoma cells were cultured in matrix gel for 0, 6, 12, 18 or 24 h before the invasion assays were performed). The scale bar indicates 100 μm (magnification, ×10).

Protein functional analysis in cholangiocarcinoma cells cultured in matrix gel. (A) Functional classification of the differentially expressed proteins in cholangiocarcinoma cells cultured with matrix gel. The altered levels of protein expression were identified by mass spectrometric analysis (see Table I) and categorized according to protein function. Note that the spots with the same identities were counted as only one spot, and each number represents the percentage among the total number of proteins identified. (B) The expression levels of L-plastin in RMCCA1 cells following culture in matrix gel for 24 h were determined by western blot analysis. β-actin was used as a loading control.

Effect of L-plastin on cholangiocarcinoma cell invasion. (A) The expression levels of L-plastin and β-actin in RMCCA1 cells transfected with either control dsRNA or L-plastin siRNA were determined by western blotting. Lane 1 represents protein extracted from RMCCA1 cells treated with control dsRNA, and lane 2 represents protein extracted from RMCCA1 cells treated with L-plastin siRNA. (B) Immunofluorescence detection by confocal microscopy. The cells were transfected with either control dsRNA or L-plastin siRNA. The cells were then triple-stained with monoclonal L-plastin antibody (red), phalloidin (green, to reveal filamentous actin) or TOPO3 (blue, to reveal the nucleus). The scale bar indicates 10 μm. (C) Box plots comparing the number of cholangiocarcinoma cell invasion events in cholangiocarcinoma cells treated with the control (dsRNA) and L-plastin siRNA (*P<0.001 by analysis of variance, compared with the control).

Expression of L-plastin was shown in cholangiocarcinoma specimens by immunohistochemical staining. L-plastin was mainly localized within the nucleus. (A) Negative L-plastin staining; (B) positive L-plastin staining in the nuclei of tumor cells; and (C) positive L-plastin staining in the cytoplasm of tumor cells. The scale bar indicates 100 μm (magnification, ×200).

A summary of upregulated proteins expressed in cholangiocarcinoma cells cultured in matrix gel, as identified by Q-TOF MS and MS/MS analyses.

Functional category and protein name GI number Mr pI Score Coverage % Ratio Gene ID Cellular component
Actin-binding protein
 L-plastin 62087548 56,196 5.21 52 6 4.6 LCP1, PLS2 Cytoplasm, cell membrane, cytoskeleton
 Cytovillin 2 (Ezrin) 340217 68,233 5.80 335 13 3.9 VIL2, EZR Cytoplasm, cell membrane, cytoskeleton
 ARP3 actin-related protein 3 homolog 5031573 47,797 5.61 150 6 3.5 ACTR3 Cytoskeleton
 α-actinin-4 2804273 102,661 5.27 72 2 3.0 ACTN4 Cytoplasm, nucleus
 Adenylyl cyclase-1 associated protein 116241280 52,222 8.27 54 10 2.6 CAP1 Cell membrane
 Fascin 4507115 55,123 6.84 160 19 2.5 FSCN1 Cytoplasm, cytoskeleton
 Cofilin-1 5031635 18,719 8.22 129 17 2.3 CFL1 Cytoplasm, nucleus, cell membrane, cytoskeleton
Energy metabolism
 Pyruvate Kinase (Pkm2) 67464392 60,277 8.22 166 20 7.3 PKM2 Cytoplasm, nucleus
 Phosphoglycerate kinase 1 4505763 44,985 8.30 439 20 6.3 PGK1, PGKA Cytoplasm
 Aldolase A 28614 39,706 8.34 267 11 3.5 ALDOA, ALDA Cytoplasm, nucleus
 α-enolase (phosphopyruvatehydratase) 693933 47,421 7.01 148 22 2.4 ENO1 Cytoplasm, nucleus
 L-lactate dehydrogenase A chain 126047 36,950 8.44 85 18 2.3 LDHA, PIG19 Cytoplasm
 ATP synthase, H+ transporting, mitochondrial F1 complex 4757810 59,828 9.16 182 17 13.5 ATP5A1, ATP5F1 Mitochondrion, Mitochondrion inner membrane
 Dihydrolipoamidesuccinyl transferase 643589 48,896 8.90 165 7 3.8 DLST Mitochondrion
 Citrate synthase 33337556 51,942 8.45 169 5 3.4 CS Mitochondrion
 Fumaratehydratase, mitochondrial 182794 50,524 7.23 305 11 2.7 FH Mitochondrion, cytoplasm
 Glutamate dehydrogenase 4885281 61,701 7.66 197 16 3.9 GLUD1 Mitochondrion
 Dihydrolipoamide dehydrogenase 83753870 50,656 6.50 236 9 2.2 DLD Mitochondrion
 acyl-Coenzyme A dehydrogenase 76496475 68,414 8.76 233 10 2.1 ACADVL Mitochondrion, mitochondrion inner membrane
 Transketolase 37267 68,435 7.90 102 16 2.8 TKT Cytoplasm, nucleus
Molecular chaperone
 Tumor rejection antigen 1, Endoplasmin 74755280 92,282 4.77 89 4 11.9 GRP94, TRA1, HSP90B1 Endoplasmic reticulum
 T-complex protein 1 subunit γ 14124984 60,934 6.10 157 7 6.3 CCT3, CCTG Cytoplasm
 Heat shock protein HSP 90-α 154146191 85,006 4.94 163 5 5.2 HSP90AA1 Cytoplasm
 Heat shock protein HSP 90-β 119602173 57,868 4.92 59 2 2.3 HSP90AB1 Cytoplasm
 Stress-induced-phosphoprotein)1 (Hsp70/Hsp90-organizing protein 5803181 63,227 6.40 145 19 3.8 STIP1 Cytoplasm, nucleus
 60 kDa heat shock protein 77702086 61,346 5.70 580 16 5.0 HSPD1, HSP60 Mitochondrion
 Heat shock protein 386785 70,110 5.42 404 10 4.4 HSPA1L Cytoplasm
 Heat shock 70 kDa protein 8 5729877 71,082 5.37 203 13 3.8 HSPA8 Cytoplasm
 Stress-70 protein, mitochondrial 21264428 73,920 5.87 70 6 3.7 HSPA9 Mitochondrion
 78 kDa glucose-regulated protein 386758 72,185 5.03 251 7 4.1 GRP78, HSPA5 Endoplasmic reticulum
 T-complex polypeptide 1 36796 60,869 6.03 197 9 4.0 TCP1 Cytoplasm, cytoskeleton
 Nucleophosmin (nucleolarphosphoprotein B23, numatrin) 15214852 32,760 4.64 198 12 3.3 NPM1, NPM Cytoplasm, nucleus, cytoskeleton
 Calreticulin 4757900 48,283 4.29 109 12 2.3 CALR Cytoplasm, endoplasmic reticulum, extracellular matrix, secreted
Structural molecule
 Tubulin, β, 2 5174735 50,255 4.79 282 14 3.8 TUBB2C, TUBB4B Cytoplasm, cytoskeleton, microtubule
 α-tubulin 37492 50,810 5.02 123 13 2.6 TUBA4A, TUBA1 Cytoplasm, cytoskeleton, microtubule
Cytoskeleton function
 Keratin, type I cytoskeletal 17 4557701 48,361 4.97 303 28 3.7 KRT17 Cytoplasm, intermediate filament, keratin
 Keratin, type I cytoskeletal 18 30311 47,305 5.27 558 28 3.5 KRT18, PIG46 CYK18 Cytoplasm, intermediate filament, keratin
 Keratin, type I cytoskeletal 19 24234699 44,079 5.04 455 44 2.1 KRT19 Intermediate filament, keratin
 Keratin, type II cytoskeletal 6A 5031839 60,293 8.09 248 29 5.8 KRT6A Intermediate filament, keratin
 Keratin, type II cytoskeletal 2 epidermal 908801 60,448 8.09 422 15 4.3 KRT2 Intermediate filament, keratin
 Keratin, type II cytoskeletal 8 181573 53,529 5.52 238 9 4.3 KRT8, CYK8 Cytoplasm, Intermediate filament, keratin, nucleus
 Keratin, type II cytoskeletal 7 12803727 51,444 5.42 287 36 3.5 KRT7 Cytoplasm, intermediate filament, keratin
Transcription regulation
 Far upstream element-binding protein 1 17402900 67,690 7.18 111 4 4.1 FUBP1 Nucleus
 ETS translocation variant 5 221042722 65,643 5.69 174 9 2.6 ERM Nucleus
Translation
 Ribosomal protein P0 4506667 34,423 5.71 193 14 3.5 RPLP0 Cytoplasm, nucleus
 Tyrosyl-tRNAsynthetase 4507947 59,448 6.61 403 16 2.4 YARS Cytoplasm
 Heterogeneous nuclear ribonucleoprotein L 11527777 64,617 8.49 173 6 3.9 HNRNPL, HNRPL, P/OKcl.14 Cytoplasm, nucleus
 Heterogeneous nuclear ribonucleoproteins A2/B1 4504447 36,041 8.67 188 13 3.2 HNRNPA2B1 Cytoplasm, nucleus, spliceosome
 Heterogeneous nuclear ribonucleoprotein K 460789 51,325 5.13 88 12 2.0 HNRNPK, HNRPK Cytoplasm, nucleus, spliceosome
Calcium ion binding protein
 Annexin A1 4502101 38,918 6.57 124 26 3.9 ANXA1, ANX1, LPC1 Cytoplasm, nucleus, cell membrane
 Annexin A2 56967118 36,634 8.32 210 13 2.1 ANXA2 Basement membrane, extracellular matrix
Signal transduction
 14-3-3 protein epsilon 5803225 29,326 4.63 136 26 2.5 YWHAE Cytoplasm
 14-3-3 protein β/α 4507949 28,179 4.76 315 23 2.2 YWHAB Cytoplasm
Elongation factor
 Elongation factor Tu 704416 49,851 7.70 229 19 3.9 TUFM Mitochondrion
Proteasome regulatory
 26S proteasome non-ATPase regulatory subunit 12 4506221 53,270 7.53 127 6 3.3 PSMD12 Proteasome, nucleus, cytoplasm
GTPase activation
 Human rab GDI 285975 51,088 5.94 347 15 3.3 RABGDIB Cytoplasm
Chromatin regulator
 Protein arginine 20070220 73,322 5.88 43 1 3.2 PRMT5 Cytoplasm, nucleus
N-methyltransferase 5
Glycan metabolism
 Protein kinase C substrate 80K-H isoform 2 48255891 60,110 4.34 51 8 2.6 PRKCSH Endoplasmic reticulum
Protein disulfide isomerase
 Prolyl 4-hydroxylase, β polypeptide 20070125 57,480 4.76 586 24 2.6 P4HB Endoplasmic reticulum
Protease inhibitor
 Serine proteinase inhibitor 62898301 42,857 5.90 167 9 2.3 SERPIN Secreted

Correlation between L-plastin expression and the clinicopathological features of cholangiocarcinoma patients.

L-plastin expression
Characteristics Negative Positive P-value
Gender
 Male 8 5 1.00
 Female 7 4
Tumor differentiation
 Well 5 3 1.00
 Moderate and poor 10 6
Lymph node metastasis
 No 5 4 0.65
 Yes 10 5
Distant metastasis
 No 11 6 1.00
 Yes 4 3